wikidoc - User contributions [en]

Sandbox:Aneeza

2021-04-06T12:30:17Z

Aneeza Jamshed:

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

=LIBMAN-SACK ENDOCARDITIS:=

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease and infective endocarditis with valvular insufficeincy. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

===HISTORICAL PERSPECTIVES:===
Libman and Sack in 1924, first coined this term for the sterile verrucous vegetations of the mitral and aortic valves in four patients in New York<ref name="pmidPMID: 19089657">{{cite journal| author=Lee JL, Naguwa SM, Cheema GS, Gershwin ME| title=Revisiting Libman-Sacks endocarditis: a historical review and update. | journal=Clin Rev Allergy Immunol | year= 2009 | volume= 36 | issue= 2-3 | pages= 126-30 | pmid=PMID: 19089657 | doi=10.1007/s12016-008-8113-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19089657 }} </ref>.

 

===PATHOPHYSIOLOGY:===

Endothelial dysfunction and hypercoagulable state are the two most important events in the process of non-thrombotic non-bacterial endocarditis (NTBE), that lead to vegetation formation on the valves <ref name="pmidPMID: 32536317">{{cite journal| author=Yoo BW, Lee SW, Song JJ, Park YB, Jung SM| title=Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. | journal=Lupus | year= 2020 | volume= 29 | issue= 9 | pages= 1115-1120 | pmid=PMID: 32536317 | doi=10.1177/0961203320930097 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32536317 }} </ref>. In Systemic Lupus erythematosus and other autoimmune conditions, the formation of autoantibodies may damage he native valves creating a nidus for the formation of vegetation the vegetations can be small (less than 1mm), histopathologically consisting of fibrin, platelets thrombi, mono-nuclear cells and immune complexes.<ref name="pmidpmid:24029368">{{cite journal| author=Roldan CA, Sibbitt WL, Qualls CR, Jung RE, Greene ER, Gasparovic CM | display-authors=etal| title=Libman-Sacks endocarditis and embolic cerebrovascular disease. | journal=JACC Cardiovasc Imaging | year= 2013 | volume= 6 | issue= 9 | pages= 973-83 | pmid=pmid:24029368 | doi=10.1016/j.jcmg.2013.04.012 | pmc=3941465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24029368 }} </ref>

 

===ETIOLOGY:===
The major phenomenon involved in the etiology of Lib-man sack endocarditis are Systemic Lupus Erythematosus, Malignancy and Antiphospholipid syndrome. The prevalence of NTBE in malignancy is reported to be '''1.25%''' as compared to 0.25% in general population, among which '''2.7%''' is accounted for by the solid organ malignancies. About '''33%''' prevalence is recorded in patients with either primary or secondary anti-phospholipid syndrome. A significant correlation of '''6% to 11%''' exists between lupus findings and NTBE.<ref name="pmidhttps://doi.org/10.1016/j.jaut.2007.11.011">{{cite journal| author=Schmoldt A, Benthe HF, Haberland G| title=Digitoxin metabolism by rat liver microsomes. | journal=Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | pmid=https://doi.org/10.1016/j.jaut.2007.11.011 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 }} </ref>
-

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Etiology|Etiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-04-06T12:23:45Z

Aneeza Jamshed:

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

=LIBMAN-SACK ENDOCARDITIS:=

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease and infective endocarditis with valvular insufficeincy. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

===HISTORICAL PERSPECTIVES:===
Libman and Sack in 1924, first coined this term for the sterile verrucous vegetations of the mitral and aortic valves in four patients in New York<ref name="pmidPMID: 19089657">{{cite journal| author=Lee JL, Naguwa SM, Cheema GS, Gershwin ME| title=Revisiting Libman-Sacks endocarditis: a historical review and update. | journal=Clin Rev Allergy Immunol | year= 2009 | volume= 36 | issue= 2-3 | pages= 126-30 | pmid=PMID: 19089657 | doi=10.1007/s12016-008-8113-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19089657 }} </ref>.

 

===PATHOPHYSIOLOGY:===

Endothelial dysfunction and hypercoagulable state are the two most important events in the process of non-thrombotic non-bacterial endocarditis (NTBE), that lead to vegetation formation on the valves <ref name="pmidPMID: 32536317">{{cite journal| author=Yoo BW, Lee SW, Song JJ, Park YB, Jung SM| title=Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. | journal=Lupus | year= 2020 | volume= 29 | issue= 9 | pages= 1115-1120 | pmid=PMID: 32536317 | doi=10.1177/0961203320930097 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32536317 }} </ref>. In Systemic Lupus erythematosus and other autoimmune conditions, the formation of autoantibodies may damage he native valves creating a nidus for the formation of vegetation the vegetations can be small (less than 1mm), histopathologically consisting of fibrin, platelets thrombi, mono-nuclear cells and immune complexes.<ref name="pmidpmid:24029368">{{cite journal| author=Roldan CA, Sibbitt WL, Qualls CR, Jung RE, Greene ER, Gasparovic CM | display-authors=etal| title=Libman-Sacks endocarditis and embolic cerebrovascular disease. | journal=JACC Cardiovasc Imaging | year= 2013 | volume= 6 | issue= 9 | pages= 973-83 | pmid=pmid:24029368 | doi=10.1016/j.jcmg.2013.04.012 | pmc=3941465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24029368 }} </ref>

 

===ETIOLOGY:===
The major phenomenon involved in the etiology of Lib-man sack endocarditis are Systemic Lupus Erythematosus, Malignancy and Antiphospholipid syndrome. The prevalence of NTBE in malignancy is reported to be '''1.25%''' as compared to 0.25% in general population, among which '''2.7%''' is accounted for by the solid organ malignancies. About '''33%''' prevalence is recorded in patients with either primary or secondary anti-phospholipid syndrome. A significant correlation of '''6% to 11%''' exists between lupus findings and NTBE.
-

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Etiology|Etiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-04-06T12:22:59Z

Aneeza Jamshed:

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

=LIBMAN-SACK ENDOCARDITIS:=

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease and infective endocarditis with valvular insufficeincy. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

===HISTORICAL PERSPECTIVES:===
Libman and Sack in 1924, first coined this term for the sterile verrucous vegetations of the mitral and aortic valves in four patients in New York<ref name="pmidPMID: 19089657">{{cite journal| author=Lee JL, Naguwa SM, Cheema GS, Gershwin ME| title=Revisiting Libman-Sacks endocarditis: a historical review and update. | journal=Clin Rev Allergy Immunol | year= 2009 | volume= 36 | issue= 2-3 | pages= 126-30 | pmid=PMID: 19089657 | doi=10.1007/s12016-008-8113-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19089657 }} </ref>.

 

===PATHOPHYSIOLOGY:===

Endothelial dysfunction and hypercoagulable state are the two most important events in the process of non-thrombotic non-bacterial endocarditis (NTBE), that lead to vegetation formation on the valves <ref name="pmidPMID: 32536317">{{cite journal| author=Yoo BW, Lee SW, Song JJ, Park YB, Jung SM| title=Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. | journal=Lupus | year= 2020 | volume= 29 | issue= 9 | pages= 1115-1120 | pmid=PMID: 32536317 | doi=10.1177/0961203320930097 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32536317 }} </ref>. In Systemic Lupus erythematosus and other autoimmune conditions, the formation of autoantibodies may damage he native valves creating a nidus for the formation of vegetation the vegetations can be small (less than 1mm), histopathologically consisting of fibrin, platelets thrombi, mono-nuclear cells and immune complexes.<ref name="pmidpmid:24029368">{{cite journal| author=Roldan CA, Sibbitt WL, Qualls CR, Jung RE, Greene ER, Gasparovic CM | display-authors=etal| title=Libman-Sacks endocarditis and embolic cerebrovascular disease. | journal=JACC Cardiovasc Imaging | year= 2013 | volume= 6 | issue= 9 | pages= 973-83 | pmid=pmid:24029368 | doi=10.1016/j.jcmg.2013.04.012 | pmc=3941465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24029368 }} </ref>

 

=== ETIOLOGY: ===
The major phenomenon involved in the etiology of Lib-man sack endocarditis are Systemic Lupus Erythematosus, Malignancy and Antiphospholipid syndrome. The prevalence of NTBE in malignancy is reported to be '''1.25%''' as compared to 0.25% in general population, among which '''2.7%''' is accounted for by the solid organ malignancies. About '''33%''' prevalence is recorded in patients with either primary or secondary anti-phospholipid syndrome. A significant correlation of '''6% to 11%''' exists between lupus findings and NTBE.
-

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Etiology|Etiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-04-06T12:11:37Z

Aneeza Jamshed: added data

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

=LIBMAN-SACK ENDOCARDITIS:=

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease and infective endocarditis with valvular insufficeincy. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

===HISTORICAL PERSPECTIVES:===
Libman and Sack in 1924, first coined this term for the sterile verrucous vegetations of the mitral and aortic valves in four patients in New York<ref name="pmidPMID: 19089657">{{cite journal| author=Lee JL, Naguwa SM, Cheema GS, Gershwin ME| title=Revisiting Libman-Sacks endocarditis: a historical review and update. | journal=Clin Rev Allergy Immunol | year= 2009 | volume= 36 | issue= 2-3 | pages= 126-30 | pmid=PMID: 19089657 | doi=10.1007/s12016-008-8113-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19089657 }} </ref>.

 

===PATHOPHYSIOLOGY:===

Endothelial dysfunction and hypercoagulable state are the two most important events in the process of non-thrombotic non-bacterial endocarditis (NTBE), that lead to vegetation formation on the valves <ref name="pmidPMID: 32536317">{{cite journal| author=Yoo BW, Lee SW, Song JJ, Park YB, Jung SM| title=Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. | journal=Lupus | year= 2020 | volume= 29 | issue= 9 | pages= 1115-1120 | pmid=PMID: 32536317 | doi=10.1177/0961203320930097 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32536317 }} </ref>. In Systemic Lupus erythematosus and other autoimmune conditions, the formation of autoantibodies may damage he native valves creating a nidus for the formation of vegetation.<ref name="pmidpmid:24029368">{{cite journal| author=Roldan CA, Sibbitt WL, Qualls CR, Jung RE, Greene ER, Gasparovic CM | display-authors=etal| title=Libman-Sacks endocarditis and embolic cerebrovascular disease. | journal=JACC Cardiovasc Imaging | year= 2013 | volume= 6 | issue= 9 | pages= 973-83 | pmid=pmid:24029368 | doi=10.1016/j.jcmg.2013.04.012 | pmc=3941465 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24029368 }} </ref>
-

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Etiology|Etiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-04-04T12:33:21Z

Aneeza Jamshed:

Sandbox:Aneeza

2021-04-04T12:31:37Z

Aneeza Jamshed: added data

Sandbox:Aneeza

2021-04-04T12:07:57Z

Aneeza Jamshed: ADDED MICROCHAPTER

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

=LIBMAN-SACK ENDOCARDITIS:=

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease and infective endocarditis with valvular insufficeincy. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

===HISTORICAL PERSPECTIVES:===
Libman and Sack in 1924, first coined this term for the sterile verrucous vegetations of the mitral and aortic valves in patients of Systemic Lupus Erythematosus<ref name="pmidPMID: 19089657">{{cite journal| author=Lee JL, Naguwa SM, Cheema GS, Gershwin ME| title=Revisiting Libman-Sacks endocarditis: a historical review and update. | journal=Clin Rev Allergy Immunol | year= 2009 | volume= 36 | issue= 2-3 | pages= 126-30 | pmid=PMID: 19089657 | doi=10.1007/s12016-008-8113-y | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19089657 }} </ref>.

 

=== PATHOPHYSIOLOGY: ===

{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|} 

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Risk Factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-04-04T11:34:29Z

Aneeza Jamshed: added the overview of the topic

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

==LIBMAN-SACK ENDOCARDITIS:==

===OVERVIEW:===
Libman-sack endocarditis is the one of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]. It may also be a finding in malignancy with the non-bacterial non-thrombotic involvement of the valves, most commonly the aortic and mitral valve. The most common complications include embolic phenomenon like cerebrovascular disease. The disease activity and titer of the antibodies in Systemic Lupus Erythematosus can be linked to Libman-sack Endocarditis<ref name="pmidPMID: 20422938">{{cite journal| author=Carrillo-Esper R, Carrillo-Córdova JR, Carrillo-Córdova LD, Carrillo-Córdova CA| title=[Libman-Sacks endocarditis]. | journal=Gac Med Mex | year= 2010 | volume= 146 | issue= 1 | pages= 67-9 | pmid=PMID: 20422938 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20422938 }} </ref>.

=<nowiki>=</nowiki>=
<ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer. | journal=Surg Oncol Clin N Am | year= 2016 | volume= 25 | issue= 3 | pages= 439-45 | pmid=27261907 | doi=10.1016/j.soc.2016.02.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27261907 }} </ref> ===
[[File:Atypical Bcell gif.gif|thumb|200px|none|High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=17 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]]

{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|} 

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Risk Factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-01-18T10:33:03Z

Aneeza Jamshed:

<ref></ref>

__NOTOC__

===={{CMG}}; {{AE}} {{Aneeza Jamshed}}====

==LIBMAN-SACK ENDOCARDITIS:==

===OVERVIEW:===
Libman-sack endocarditis is the on of the cardiac manifestations of autoimmune systemic diseases most commonly [[Systemic lupus erythematosus|Systemic Lupus Erythematosus]]
<references group="Mee J, Dong H (2007). " Epidemiology of Libman-sack endocarditis". " />
.

=<nowiki>=</nowiki>=
<ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer. | journal=Surg Oncol Clin N Am | year= 2016 | volume= 25 | issue= 3 | pages= 439-45 | pmid=27261907 | doi=10.1016/j.soc.2016.02.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27261907 }} </ref> ===
[[File:Atypical Bcell gif.gif|thumb|200px|none|High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=17 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]]

{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|} 

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Risk Factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

Sandbox:Aneeza

2021-01-15T08:47:32Z

Aneeza Jamshed:

__NOTOC__

={{CMG}}; {{AE}} {{Aneeza Jamshed}}=
Libman-sack Endocarditis

<ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer. | journal=Surg Oncol Clin N Am | year= 2016 | volume= 25 | issue= 3 | pages= 439-45 | pmid=27261907 | doi=10.1016/j.soc.2016.02.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27261907 }} </ref>

[[File:Atypical Bcell gif.gif|thumb|200px|none|High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=17 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]]

{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|} 

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Risk Factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}

User:Aneeza Jamshed

2021-01-15T08:33:27Z

Aneeza Jamshed:

Resident Cardiology

Volunteer Wikidoc reseach scholar

Sandbox:Aneeza

2021-01-15T06:35:29Z

Aneeza Jamshed: Added heading of the topic

__NOTOC__

== {{CMG}}; {{AE}} {{Aneeza Jamshed}} ==
Libman-Sacks Endocarditis
Practice here.

<ref name="pmid27261907">{{cite journal| author=Mao Y, Yang D, He J, Krasna MJ| title=Epidemiology of Lung Cancer. | journal=Surg Oncol Clin N Am | year= 2016 | volume= 25 | issue= 3 | pages= 439-45 | pmid=27261907 | doi=10.1016/j.soc.2016.02.001 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27261907 }} </ref>

[[File:Atypical Bcell gif.gif|thumb|200px|none|High-power field of peripheral blood smear revealing a large, atypical B cell with mild cytoplasmic expansion, coarse chromatin, multiple distinct nucleoli and peripheral vacuolation.[https://openi.nlm.nih.gov/detailedresult.php?img=PMC2944189_1752-1947-4-300-2&query=waldenstrom+macroglobulinaemia&it=xg&req=4&npos=17 Source: Charakidis M. et al, Department of Haematology-Oncology, Royal Hobart Hospital, Tasmania, 7000, Australia.]]]

{|
|+'''Classification of Waldenstrom macroglobulinemia (WM) and Related Disorders'''
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
|-
! align="center" style="background:#DCDCDC;" + |IgM monoclonal protein
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
|-
! align="center" style="background:#DCDCDC;" + |Bone marrow infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to IgM
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
|-
! align="center" style="background:#DCDCDC;" + |Symptoms attributable to tumor infiltration
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
| style="background:#F5F5F5;" align="center" + | -
|} 

{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
|-
| colspan="1" style="text-align:center; background:DarkGray" |
'''Libman-Sacks endocarditis Microchapters'''

|- bgcolor="LightGrey"
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Overview|Overview]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Historical Perspective|Historical Perspective]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Pathophysiology|Pathophysiology]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Epidemiology and Demographics|Epidemiology and Demographics]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Risk Factors|Risk Factors]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Natural History, Complications and Prognosis|Natural History, Complications and Prognosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Diagnosis|Diagnosis]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#History and Symptoms|History and Symptoms]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Physical Examination|Physical Examination]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Laboratory Findings|Laboratory Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Imaging Findings|Imaging Findings]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Other Diagnostic Studies|Other Diagnostic Studies]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Treatment|Treatment]]
|-
!

|- bgcolor="Pink"
!
[[Libman-Sacks endocarditis#Differentiating Libman-Sacks Endocarditis from other Diseases|Differentiating Libman-Sacks Endocarditis from other Diseases]]
|-
!

|-
|}

==Reference==
{{Reflist|2}}